EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm

Leslie Citrome iD, Kelli R Franzenburg, Mark Suett iD, Orna Tohami, Nir Sharon, Ayellet Jehassi, Eran Harary, Daisy Yu, Christoph U Correll iD

Neuropsychiatric Disease and Treatment · 2026-05 · Volume 22 · 1-16

DOI: 10.2147/ndt.s534730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychiatric Disease and Treatment, 2026-05. Verfasst von Leslie Citrome und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

TV-46000likelihood to be helped or harmedlong-acting injectable antipsychoticnumber needed to harmnumber needed to treatschizophrenia

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.
  • Global Medical Affairs, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
  • Global Medical Affairs, Teva UK Limited, Harlow, UK.
  • Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
  • Global Statistics and Data Science, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
  • Biostatistics, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.

ORCID-Profile: Leslie Citrome, Mark Suett, Christoph U Correll

Zitieren

APA

Citrome, L., Franzenburg, K. R., Suett, M., Tohami, O., Sharon, N., Jehassi, A., Harary, E., Yu, D., & Correll, C. U. (2026). Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm. Neuropsychiatric Disease and Treatment, Volume 22, 1-16. https://doi.org/10.2147/ndt.s534730

Vancouver

Citrome L, Franzenburg KR, Suett M, Tohami O, Sharon N, Jehassi A, et al. Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm. Neuropsychiatric Disease and Treatment. 2026;Volume 22:1-16. doi:10.2147/ndt.s534730

BibTeX
@article{Citrome2026,
  author = {Citrome, Leslie and Franzenburg, Kelli R and Suett, Mark and Tohami, Orna and Sharon, Nir and Jehassi, Ayellet and Harary, Eran and Yu, Daisy and Correll, Christoph U},
  title = {Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm},
  journal = {Neuropsychiatric Disease and Treatment},
  year = {2026},
  volume = {Volume 22},
  pages = {1--16},
  doi = {10.2147/ndt.s534730}
}
Kostenlos starten →